Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 - Trial NCT06354387
Access comprehensive clinical trial information for NCT06354387 through Pure Global AI's free database. This Phase 1 trial is sponsored by China Medical University Hospital and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
China Medical University Hospital
Timeline & Enrollment
Phase 1
Feb 16, 2022
Jun 01, 2025
Primary Outcome
Objective response rate(ORR)
Summary
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and
 the second most deadly malignancy in Taiwan. Despite decades' intensive studies, surgery and
 local-regional chemo-embolization, radio-frequency ablation or radiation therapy remain the
 mainstay of HCC treatments.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06354387
Non-Device Trial